PATE3: A Potential Drug Target and Biomarker (G100169851)

Target Name: PATE3

NCBI ID: G100169851

PATE3

PATE3: A Potential Drug Target and Biomarker

Pate3, also known as patiracin, is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is a member of the PAT family of transmembrane proteins, which are involved in various cellular processes, including signaling and modulation of ion channels. One of the unique features of pate3 is its ability to modulate the activity of ion channels, which are critical for the regulation of ion traffic and neurotransmitter signaling. This property makes pate3 an attractive drug target and a potential biomarker for various neurological and cardiovascular disorders.

The discovery and characterization of pate3 began in the late 1990s, when researchers identified it as a potential modulator of ion channels in brain cells. Since then, several studies have demonstrated the unique effects of pate3 on ion channels and neurotransmission. These studies have also provided insights into the underlying mechanisms that regulate pate3 activity.

One of the key features of pate3 is its ability to modulate the activity of Na+ and K+ channels. These channels are involved in the regulation of neuronal excitability and are critical for the transmission of signals in the brain. By modulating the activity of these channels, pate3 can influence the strength and direction of neurotransmitter release, as well as the overall membrane potential of the cell.

In addition to its effects on ion channels, pate3 has also been shown to play a role in modulating the release of other neurotransmitters, including dopamine, GABA, and endogenous opioids. These studies have important implications for the development of new treatments for psychiatric and neurological disorders, as well as for the treatment of chronic pain.

The potential drug targets for pate3 are vast, and research into its clinical applications is still in its infancy. Several studies have shown that pate3 can be effectively targeted with small molecules, including inhibitors of ion channels and RNA binding proteins. Other potential drug targets for pate3 include modulators of its activity on protein kinases, modulators of its localization to the endoplasmic reticulum, and inhibitors of its synthesis.

In addition to its potential as a drug target, pate3 is also a potential biomarker for various neurological and cardiovascular disorders. The modulation of ion channels by pate3 has been observed in a wide range of neurotransmitter release events, including the regulation of synaptic plasticity, learning, and memory. These studies suggest that pate3 may be a useful biomarker for the diagnosis and treatment of disorders of neurotransmission, such as Alzheimer's disease, Parkinson's disease, and schizophrenia.

In conclusion, pate3 is a unique and promising drug target and biomarker that has the potential to revolutionize our understanding of various neurological and cardiovascular disorders. Further research is needed to fully understand the mechanisms of pate3's modulation of ion channels and neurotransmission, as well as its potential as a drug and biomarker. The development of new treatments and therapies based on pate3 will be a major focus of future research in this field.

Protein Name: Prostate And Testis Expressed 3

The "PATE3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PATE3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets